Allogene Therapeutics SEC filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic CAR T product candidates. The filings cover material-event reports, operating and financial updates, common stock registration and offering activity, and clinical disclosures involving programs such as cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease.
Allogene's proxy materials describe annual meeting proposals, shareholder voting matters, board governance, executive compensation, and equity award disclosures. Other filings address Nasdaq-listed common stock, capital-structure changes, material agreements, and risk factors tied to research and development, clinical execution, regulatory matters, intellectual property, and licensed gene-editing technology used in its allogeneic CAR T programs.
Allogene Therapeutics EVP of R&D Zachary Roberts reported equity award grants and a tax-related share sale. On February 2, 2026, he was granted a stock option for 718,763 shares of common stock at an exercise price of $1.87 per share, vesting 25% on February 2, 2027 and the rest in 36 monthly installments. He also received 203,307 restricted stock units, which vest in four equal annual installments starting February 2, 2026, each RSU representing one share. The filing shows a sale of 35,700 common shares at a weighted average price of $1.77 solely to cover tax withholding on RSU vesting under a mandatory “sell to cover” arrangement, leaving him with 581,166 common shares held directly.
Allogene Therapeutics director Arie Belldegrun reported new equity awards and updated share holdings. On February 2, 2026, he was granted a stock option for 929,913 shares of common stock at an exercise price of $1.87 per share and an award of 263,033 restricted stock units (RSUs), both held directly.
Twenty-five percent of the option vests on February 2, 2027, with the balance vesting in 36 equal monthly installments. The RSUs vest in four equal annual installments starting February 2, 2026, subject to continued service. Indirect common stock holdings are reported in entities including Bellco Legacy Trust fbo Rebecka Belldegrun, Vida Ventures LLC, Vida Ventures III partnerships, and Bellco Legacy LLC, along with 2,236,816 common shares held directly.
ALLO had a Form 144 filed to permit the sale of 22,900 shares of its common stock through Morgan Stanley Smith Barney LLC on or about 02/02/2026, to be sold on NASDAQ with an aggregate market value of $40,214.69.
The shares were acquired on 01/31/2026 as restricted stock vesting under a registered compensation plan, with compensation listed as the form of payment. The filing notes that 224,730,144 shares of common stock were outstanding.
A holder of ALLO common stock has filed a Rule 144 notice to sell 24,001 shares through Morgan Stanley Smith Barney LLC on or about 02/02/2026 on NASDAQ. The aggregate market value of the planned sale is listed as $42,188.96, with issuer shares outstanding of 224,730,144.
The shares were acquired as restricted stock vesting under a registered compensation plan from the issuer on 01/31/2026, in a non-cash transaction classified as compensation. The seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Allogene Therapeutics insider Zachary Roberts has filed a Form 144 notice to sell 35,700 shares of common stock, with an aggregate market value of $63,353.22, through Morgan Stanley Smith Barney on NASDAQ around February 2, 2026.
The shares were acquired on January 31, 2026 via restricted stock vesting under a registered compensation plan, with 224,730,144 common shares outstanding. In the prior three months, Roberts sold 26,269 common shares for gross proceeds of $40,979.64. The filer represents they are not aware of undisclosed material adverse information about Allogene.
Allogene Therapeutics insider plans Rule 144 stock sale. A holder has filed to sell 4,167 shares of Allogene Therapeutics common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $7,177.66. The shares were acquired on January 31, 2026 through restricted stock vesting under a registered compensation plan.
The planned sale is expected to occur around February 2, 2026 on the NASDAQ exchange. As of the notice, 224,730,144 shares of Allogene common stock were outstanding, providing context for the relative size of this planned transaction.
A planned sale notice under Rule 144 covers 243,976 shares of Common Stock, to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ market. The shares have an aggregate market value of 438,522.46 and are part of a total of 224,730,144 shares outstanding.
The seller acquired these shares as restricted stock vesting under a registered plan from the issuer on 01/31/2026, treated as compensation. The approximate planned sale date is 02/02/2026, and the signer represents not knowing any undisclosed material adverse information about the issuer’s operations.
A holder of common stock has filed a Form 144 notice to potentially sell 16,823 shares through Morgan Stanley Smith Barney LLC on the NASDAQ, with an indicated aggregate market value of $29,051.64. The issuer reports 224,730,144 shares of common stock outstanding.
The shares to be sold were acquired as restricted stock vesting under a registered plan on January 31, 2026, treated as compensation from the issuer. The same individual previously sold 786 common shares on November 17, 2025, generating gross proceeds of $958.92.
Allogene Therapeutics, Inc. reported an insider transaction by EVP of R&D Zachary RobertsJanuary 21, 2026, Roberts sold 26,269 shares of Allogene common stock at $1.56 per share. According to the filing, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units, under a mandated “sell to cover” election in the company’s equity incentive plan, and are not a discretionary trade by Roberts.
Following this transaction, Roberts beneficially owned 616,866 shares of Allogene common stock in direct ownership.
Allogene Therapeutics, Inc. has a planned sale of 26269 shares of common stock, as disclosed in a Form 144 notice. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/21/2026 and an aggregate market value of 40929.05.
The securities were acquired on 01/20/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan. Shares outstanding were 224730144 at the time of the notice; this is a baseline figure, not the amount being sold.